ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors New AlphaMedix data showed sustained and clinically ...
Strategists warn a deeper pullback toward $1.55 remains plausible before a structural recovery attempt toward the $7–$27 ...
Let’s examine the recent performance, growth outlook, dividend-growth history, and yields of BCE and Telus to determine which is the better buy right now. The post Interested in BCE Stock? Look at ...